DEA pseudoephedrine proposal would affect about $115 mil. in Warner Wellcome retail sales.
This article was originally published in The Tan Sheet
DEA PSEUDOEPHEDRINE REG WOULD AFFECT ABOUT $115 MIL. IN WARNER WELLCOME SALES, parent company Warner-Lambert estimated in Dec. 28 comments to the Drug Enforcement Agency. Warner-Lambert complained that DEA's Oct. 31 proposed rule, which would require retailers to report all single sales involving more than 24 grams pseudoephedrine base, would "directly" affect "14 SKUs, including 13 Sudafed and Actifed and one Benadryl Decongestant product with retail sales of approximately $115 mil."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC